Opsonic Therapeutics to develop RAS and mRNA technology from Tripep
1 September 2009
Swedish company Tripep (STO:TPEP) and the German biotech company
Cosmix AG have licensed their respective technologies (RAS and mRNA
Display Library) to a newly formed US company named Opsonic
Therapeuticals Inc. within which Tripep’s RAS technology will be
The RAS technology is based on oligosaccharide linked peptides that
can redirect natural antibodies present in all humans to new targets.
Cosmix in turn has developed the mRNA Display Library technology by
which peptides that bind to a selected target rapidly are identified.
Opsonic will use Cosmix technology to identify target-binding peptides
and these are then used in RAS peptides aimed for therapeutic use.
Cosmix AG has developed a mRNA Display Library by which ligand
binding peptide sequences are rapidly identified. Cosmix has licensed
this technology to Opsonic and in return obtained a 20% ownership.
Likewise has Tripep licensed to Opsonic an exclusive license to use the
RAS technology development of new pharmaceuticals. Tripep in return has
also obtained a 20% ownership in Opsonic.
Among the founders of Cosmix are the inventors behind the two
technologies Dr Peter Wagner, Prof Matti Sällberg and Prof Anders Vahlne,
and the CEO Albert Collinson who has an extensive experience form
leading positions in US and European biotech companies.
”This is a perfect marriage between two technologies that rapidly can
generate new peptide-based pharmaceuticals that use the unexplored pool
of natural antibodies in humans. This is a completely new and effective
way to develop the RAS technology into a commercial product”, says
Opsonic’s CEO Albert Collinson.
Bookmark this page